<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005997.pub2" GROUP_ID="MENSTR" ID="399105091207432594" MERGED_FROM="" MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;/p&gt;" NOTES_MODIFIED="2008-10-22 17:12:30 +1300" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="HAK 1181" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Hormone therapy for endometriosis and surgical menopause</TITLE>
<CONTACT MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="48DB583482E26AA2000C5DBBA76CF0B0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hanan</FIRST_NAME><LAST_NAME>Al Kadri</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>halkadri@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>KFNGH</ORGANISATION><ADDRESS_1>PO Box 57374</ADDRESS_1><CITY>Riyadh</CITY><ZIP>11574</ZIP><COUNTRY CODE="SA">Saudi Arabia</COUNTRY></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="48DB583482E26AA2000C5DBBA76CF0B0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Hanan</FIRST_NAME><LAST_NAME>Al Kadri</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>halkadri@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>KFNGH</ORGANISATION><ADDRESS_1>PO Box 57374</ADDRESS_1><CITY>Riyadh</CITY><ZIP>11574</ZIP><COUNTRY CODE="SA">Saudi Arabia</COUNTRY></ADDRESS></PERSON><PERSON ID="83E2C24B82E26AA20029B854DD669DA0" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Samar</FIRST_NAME><LAST_NAME>Hassan</LAST_NAME><POSITION>Section head  IVF division</POSITION><EMAIL_1>hassans@ngha.med.sa</EMAIL_1><EMAIL_2>hassansamar@hotmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Obstetrics and Gynecology</DEPARTMENT><ORGANISATION>King Abdulaziz Medical City, National Guard Hospital</ORGANISATION><ADDRESS_2>P.O.Box 22490</ADDRESS_2><CITY>Riyadh</CITY><ZIP>11426</ZIP><COUNTRY CODE="SA">Saudi Arabia</COUNTRY><PHONE_1>+966 1 252 0088 x12227</PHONE_1><PHONE_2>mob +966505 228913</PHONE_2><FAX_1>+966 1 252 0088 x13237</FAX_1></ADDRESS></PERSON><PERSON ID="4DA2278282E26AA2000C5DBB7988FBF9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Haya</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Al-Fozan</LAST_NAME><SUFFIX>M.D, ABOG, SBOG</SUFFIX><POSITION>Consultant, Director of National and Gulf center for EBM</POSITION><EMAIL_1>hafozan@gmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>IVF and Endocrinology Unit</ORGANISATION><ADDRESS_1>King Abdulaziz Medical city</ADDRESS_1><ADDRESS_2>Mail code 1240, PO Box 22490</ADDRESS_2><CITY>Riyad</CITY><ZIP>11426 KSA</ZIP><COUNTRY CODE="SA">Saudi Arabia</COUNTRY><PHONE_1>966 1 2520088 ext:13229</PHONE_1><FAX_1>966 1 252088 ext: 13237</FAX_1></ADDRESS></PERSON><PERSON ID="C40AE7D182E26AA201650CEAF07B99D9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Ali</FIRST_NAME><LAST_NAME>Hajeer</LAST_NAME><SUFFIX>A.H.</SUFFIX><POSITION>FRC Pathology Head</POSITION><EMAIL_1>hajeera@ngha.med.sa</EMAIL_1><ADDRESS><DEPARTMENT>Pathology and Laboratory Medicine</DEPARTMENT><ORGANISATION>King Abdulaziz Medical City</ORGANISATION><ADDRESS_1>National Guard Health Affairs</ADDRESS_1><ADDRESS_2>PO Box 22490</ADDRESS_2><CITY>Riyadh</CITY><ZIP>11426</ZIP><COUNTRY CODE="SA">Saudi Arabia</COUNTRY><PHONE_1>+966 1 252 008 x12728</PHONE_1><FAX_1>+966 1 252 0130</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Minor update: 25/03/08&lt;/p&gt;" NOTES_MODIFIED="2008-07-10 16:12:04 +1200" NOTES_MODIFIED_BY="jane clarke">
<UP_TO_DATE>
<DATE DAY="10" MONTH="7" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="3" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="30" MONTH="3" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2009"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2009"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:23:12 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY></WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>National Guard Health Affairs, Cochrane Review Group</NAME>
<COUNTRY CODE="SA">Saudi Arabia</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Cochrane Menstrual Disorders And Subfertility Group</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-22 17:12:30 +1300" MODIFIED_BY="jane clarke">
<SUMMARY MODIFIED="2008-08-21 09:46:28 +1200" MODIFIED_BY="jane clarke">
<TITLE MODIFIED="2008-08-20 11:29:34 +1200" MODIFIED_BY="[Empty name]">Hormone therapy for women with endometriosis and surgical menopause</TITLE>
<SUMMARY_BODY MODIFIED="2008-08-21 09:46:28 +1200" MODIFIED_BY="jane clarke">
<P>Endometriosis is known to result in variable severity of symptoms. For some women bilateral removal of the ovaries (oophorectomy) with or without an hysterectomy may be required to manage symptoms. This brings women into premature menopause. It is thought that hormone replacement therapy may enhance the recurrence of the disease due to its effect on the remaining endometriotic deposits in the pelvis. Only two small randomised controlled were identified in the literature that looked at this problem. Further research is required to clarify the effect of different hormone replacement therapy types on the recurrence of the disease and the associated pain including during sex.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-08-21 09:46:28 +1200" MODIFIED_BY="jane clarke">
<ABS_BACKGROUND MODIFIED="2008-08-21 09:35:01 +1200" MODIFIED_BY="jane clarke">
<P>Endometriosis is characterized by the presence of ectopic endometrial tissue that might lead to many distressing and debilitating symptoms. Despite available studies supporting standard hormone therapy for women with endometriosis and post-surgical menopause, there is still a concern that estrogens may induce a recurrence of the disease and its symptoms.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-08-20 11:01:13 +1200" MODIFIED_BY="[Empty name]">
<P>This review aimed to look at pain and disease recurrence in women with endometriosis who used hormone therapy for post-surgical menopause.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-08-20 11:06:14 +1200" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Menstrual Disorders and Subfertility Group Specialized Register (March 2008), Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> 2008, Issue 3), MEDLINE (1966 to March 2008), EMBASE (1980 to March 2008), and references lists of articles. Relevant journals and conference proceedings were handsearched.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-08-20 13:58:34 +1200" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials studying hormone therapy for women with endometriosis in post-surgical menopause.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-08-20 11:08:02 +1200" MODIFIED_BY="[Empty name]">
<P>Review authors assessed the eligibility of trials and their quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-08-20 11:28:43 +1200" MODIFIED_BY="[Empty name]">
<P>Two studies fulfilled our inclusion criteria. One trial compared the nonstop transdermal application of 17&#946;-estradiol (0.05 mg/day) combined with cyclic medroxy progesterone acetate (10 mg per day) for 12 days per month in women with a conserved uterus with nonstop tibolone (2.5 mg/day). The second trial used sequential administration of estrogens and progesterone with two 22 cm<SUP>2</SUP> patches applied weekly to produce a controlled release of 0.05 mg/day. Micronized progesterone was administered orally (200 mg/day) for 14 days with a 16-day interval free of treatment.  </P>
<P>Pain and dyspareunia<BR/>The first trial reported recurrence of pain in the estrogen and progesterone arm in 4/10 of women compared with 1/11 in the tibilone arm. In the latter, 4/115 women reported recurrence of pain in the treatment group compared with 0/57 patients in the no-treatment arm. Neither finding was statistically different.</P>
<P>Confirmed recurrence or exacerbation of endometriosis<BR/>This outcome was not reported in the first trial. The second found that 2/115 of the treatment group developed recurrence of endometriosis with no recurrence reported in the no-treatment group. This was not statistically significant. No woman was re-operated on in the no-treatment group compared with 2/115 in the treatment group.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-08-21 09:46:28 +1200" MODIFIED_BY="jane clarke">
<P>Hormone replacement therapy for women with endometriosis in post-surgical menopause could result in pain and disease recurrence. However, the evidence in the literature is not strong enough to suggest depriving severely symptomatic patients from this treatment. There is a need for more randomised controlled studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-22 17:12:30 +1300" MODIFIED_BY="jane clarke">
<BACKGROUND MODIFIED="2008-08-20 13:21:00 +1200" MODIFIED_BY="[Empty name]">
<P>Endometriosis is characterized by the presence of ectopic endometrial tissue that can lead to distressing and debilitating symptoms. The prevalence of endometriosis in the general population is not known but it has been estimated to affect about 7% of women of reproductive age (<LINK REF="REF-Haney-1991" TYPE="REFERENCE">Haney 1991</LINK>). Estimates of prevalence based upon visualization of the pelvic organs range from 1% to 50% (<LINK REF="REF-Chatman-1982" TYPE="REFERENCE">Chatman 1982</LINK>; <LINK REF="REF-Sangi_x002d_Haghpeykar1995" TYPE="REFERENCE">Sangi-Haghpeykar1995</LINK>).</P>
<P>There is considerable controversy regarding the optimal treatment of endometriosis. The choice of therapy usually depends upon the severity of symptoms, extent and location of the disease, desire for pregnancy, and a woman's age (<LINK REF="REF-Shaw-1992" TYPE="REFERENCE">Shaw 1992</LINK>).</P>
<P>Endometriosis is generally believed to be an estrogen-dependent disorder. The many observations that support this view include amelioration of pre-existing endometriosis after surgical menopause (<LINK REF="REF-Kitawaki-2002" TYPE="REFERENCE">Kitawaki 2002</LINK>) or natural menopause (<LINK REF="REF-Kitawaki-2002" TYPE="REFERENCE">Kitawaki 2002</LINK>), and the growth of endometrial tissue in animals on estrogen therapy (<LINK REF="REF-Bruner_x002d_Tran-2002" TYPE="REFERENCE">Bruner-Tran 2002</LINK>). This has led to the use of gonadotropin-releasing hormone agonists (GnRHa) to induce ovarian suppression, which is widely accepted as a treatment for endometriosis. The fall in estrogen levels following treatment with GnRHa leads to a significant improvement in the stage and symptoms of endometriosis (<LINK REF="REF-Donnez-1997" TYPE="REFERENCE">Donnez 1997</LINK>; <LINK REF="REF-Fedele-2004" TYPE="REFERENCE">Fedele 2004</LINK>). This may be used as a short-term strategy due to the risk of developing osteoporosis (<LINK REF="REF-Agarwal-2002" TYPE="REFERENCE">Agarwal 2002</LINK>).</P>
<P>Inducing menopause, either medically or surgically, has become one of the strategies for the management of the symptoms of endometriosis. Hysterectomy is commonly performed for endometriosis. Generally the ovaries are conserved in order to avoid the need for lengthy hormone replacement therapy. Removal of both ovaries is usually considered appropriate when the woman is approaching menopause or in the presence of extensive disease. Sometimes hysterectomy and bilateral salpingoophorectomy are inadequate if deep disease is left untreated (<LINK REF="REF-Donnez-1997" TYPE="REFERENCE">Donnez 1997</LINK>; <LINK REF="REF-Fedele-2004" TYPE="REFERENCE">Fedele 2004</LINK>; <LINK REF="REF-Matorras-2002" TYPE="REFERENCE">Matorras 2002</LINK>).</P>
<P>Surgical and medical menopause are frequently associated with hypo-estrogenic side effects and changes in bone density, although these may resolve with treatment (<LINK REF="REF-Slenvenson-1989" TYPE="REFERENCE">Slenvenson 1989</LINK>). A number of studies have been conducted which investigated the effects of GnRHa ovarian suppression and progress of endometriosis (<LINK REF="REF-Cedars-1990" TYPE="REFERENCE">Cedars 1990</LINK>; <LINK REF="REF-Makarainen-1996" TYPE="REFERENCE">Makarainen 1996</LINK>; <LINK REF="REF-Riis-1990" TYPE="REFERENCE">Riis 1990</LINK>; <LINK REF="REF-Surrey-1990" TYPE="REFERENCE">Surrey 1990</LINK>). Others have investigated the effect of an add-back regimen that uses either estrogen or progestogens to avoid hot flushes (<LINK REF="REF-Cedars-1990" TYPE="REFERENCE">Cedars 1990</LINK>; <LINK REF="REF-Riis-1990" TYPE="REFERENCE">Riis 1990</LINK>; <LINK REF="REF-Surrey-1992" TYPE="REFERENCE">Surrey 1992</LINK>). Tibolone has also been evaluated, and shown to be effective, in a single small trial (<LINK REF="REF-Tabkin-1997" TYPE="REFERENCE">Tabkin 1997</LINK>). The results of this study showed that tibolone suppressed painful symptoms, vasomotor symptoms, and urinary markers of bone turnover.</P>
<P>Despite available evidence supporting standard hormone therapy for women with endometriosis post-surgical menopause (<LINK REF="REF-Lindsay-1996" TYPE="REFERENCE">Lindsay 1996</LINK>; <LINK REF="REF-Rock-1992" TYPE="REFERENCE">Rock 1992</LINK>), many gynaecologists remain concerned that estrogens may induce a recurrence of the disease and its symptoms. Several studies (<LINK REF="REF-Sagsaveen-2003" TYPE="REFERENCE">Sagsaveen 2003</LINK>) have been carried out to assess the effect of hormone therapy on hypo-estrogenic symptoms induced by GnRH analogues for women with endometriosis but only a few have addressed its effect on women experiencing post-surgical menopause.</P>
<P>The aim of this systematic review of published literature is to critically appraise the literature describing the risk of pain and disease recurrence among women who have had endometriosis and undergone bilateral salpingoophorectomy (BSO), with or without hysterectomy, and subsequently received hormone therapy.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2008-08-20 12:02:24 +1200" MODIFIED_BY="[Empty name]">
<P>This review aimed to look at pain recurrence for women with endometriosis who used hormone therapy for post-surgical menopause.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-08-21 09:46:40 +1200" MODIFIED_BY="jane clarke">
<SELECTION_CRITERIA MODIFIED="2008-08-21 09:46:40 +1200" MODIFIED_BY="jane clarke">
<CRIT_STUDIES MODIFIED="2008-08-21 09:46:38 +1200" MODIFIED_BY="jane clarke">
<P>All randomised controlled trials (RCTs) which studied women with endometriosis taking estrogen replacement therapy (ERT) or hormone replacement therapy (HRT) following surgical menopause.</P>
<P>Non-randomized and quasi-randomized controlled trials were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-08-21 09:46:40 +1200" MODIFIED_BY="jane clarke">
<P>
<B>Inclusion criteria<BR/>
</B>Women with ectopic endometrial tissue that potentially could lead to distressing and debilitating symptoms regardless of the size and site of the deposits. Women who had undergone bilateral oophorectomy for treatment of endometriosis. Surgical menopause was defined as menopause due to surgical excision of both ovaries, with or without hysterectomy.</P>
<P>Exclusion criteria<BR/>Studies with participants who didn't fulfil the inclusion criteria were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-08-20 12:25:27 +1200" MODIFIED_BY="[Empty name]">
<P>1. Estrogen versus placebo<BR/>2. Estrogen versus progestogen<BR/>3. Estrogen versus tibolone<BR/>4. Estrogen versus estrogen plus progestogen<BR/>5. Estrogen versus other hormones<BR/>We included all dosages, routes of administration, and frequency or duration of intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-08-20 12:31:02 +1200" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome measures</B>
</P>
<UL>
<LI>Pain and dyspareunia (painful intercourse)</LI>
</UL>
<P>The method of pain assessment was identified and, if possible, the participants were grouped into three major groups of: mild, moderate, or severe pain.</P>
<P>
<B>Secondary outcomes measures</B>
</P>
<UL>
<LI>Confirmed recurrence or exacerbation of endometriosis (recurrence of disease symptoms that were suspected clinically and confirmed by tissue biopsy or ultrasound findings).</LI>
<LI>Diagnosis of cancer (defined as the development of adenocarcinoma at the site of the endometriotic deposits).</LI>
<LI>Mortality (death related directly or indirectly to the disease, its treatment, or both).</LI>
<LI>Re-operation for endometriosis.</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-08-20 12:37:11 +1200" MODIFIED_BY="[Empty name]">
<P>We obtained relevant trials from the following sources (with the most recent search done on 18th March 2008).</P>
<P>1) We searched the Cochrane Menstrual Disorders and Subfertility Group (MDSG) Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) (March 2008).</P>
<P>2) We searched MEDLINE using the optimally sensitive strategy for the identification of RCTs developed for The Cochrane Collaboration and a specific search strategy developed with input from the MDSG Trial Search Co-ordinators (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>).</P>
<P>3) We searched EMBASE using a search strategy adapted from that developed for The Cochrane Collaboration for the identification of RCTs and combined this with a specific search strategy developed with input from the MDSG Trial Search Co-ordinators (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>4) We searched CINHAL (1982 to 18 March 2008) (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>5) We searched PSYCINFO (1982 to 18th March 2008) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<P>6) We also searched reference lists of standard Obstetrics and Gynaecology textbooks, review articles, and relevant trials.</P>
<P>7) We sent letters seeking information about unpublished or incomplete, ongoing trials to investigators known to be involved in previous trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-08-20 13:09:11 +1200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Selection of the studies</HEADING>
<P>Four review authors (HK, AH, SH, HF) undertook study selection. We used the search strategy described above to obtain titles and abstracts of studies that may be relevant to the review. HK and AH independently screened the titles and abstracts of promising articles. They discarded studies that were not applicable and retained studies and reviews that might have included relevant data or information. HK and AH independently assessed retrieved abstracts and ordered the full texts of these studies when necessary. We did not require translation of any studies reported in non-English language journals. Where more than one publication of a trial existed, we included only the publication with the most complete data. We resolved any disagreements through discussion. No crossover trials were included. </P>
<P>SH and HF independently assessed the quality of studies to be included, without blinding to authorship or journal of publication, using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.<I> </I>The review authors resolved discrepancies by discussion with HK and AH<I> </I>(see Table 1).</P>
<SUBSECTION>
<HEADING LEVEL="6">1. Selection bias (randomization and allocation concealment)</HEADING>
<P>We assigned a quality score for each trial using the following criteria.<BR/>A. Adequate concealment of allocation: telephone randomization, consecutively numbered sealed opaque envelopes.<BR/>B. Unclear whether adequate concealment of allocation: list or table used, sealed envelopes, study did not report on any concealment approach.<BR/>C. Inadequate concealment of allocation: open list of random number tables, use of case record numbers, dates of birth, or days of the week.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">2. Performance bias (blinding of participants, researchers and outcome assessors)</HEADING>
<P>We assessed blinding using the following criteria:<BR/>A. blinding of participants (yes, no, or unclear);<BR/>B. blinding of caregiver (yes, no, or unclear);<BR/>C. blinding of outcome assessment (yes, no, or unclear).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">3. Attrition bias (loss of participants, for example through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We assessed completeness of follow up using the following criteria:<BR/>A. less than 5% loss of participants;<BR/>B. 5% to 10% loss of participants;<BR/>C. more than 10% and less than 20% loss of participants;<BR/>D. more than 20% loss of participants.<BR/>We excluded all studies with more than 20% loss to follow up.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Analysis</HEADING>
<P>For dichotomous outcomes (mortality, recurrence, cancer diagnosis, pain, dyspareunia, and re-operation) we expressed results as odds ratios (OR) with 95% confidence intervals (CI). No continuous data were reported hence weighted mean differences were not used.</P>
<P>We analysed data on an intention-to-treat basis. We included in the analysis all participants with available data in the group to which they are allocated, regardless of whether or not they received the allocated intervention.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Heterogeneity</HEADING>
<P>Heterogeneity was not tested as the two identified studies used different interventions.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>No subgroup analysis was possible from this data.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-10-22 17:12:30 +1300" MODIFIED_BY="jane clarke">
<STUDY_DESCRIPTION MODIFIED="2008-08-21 09:46:48 +1200" MODIFIED_BY="jane clarke">
<P>HK and AH carried out data extraction independently using standard data extraction forms.<BR/>We intended to extract the following information from the two studies included in the review:<BR/>1. randomisation;<BR/>2. allocation concealment;<BR/>3. trial design multicentre or single centre, single phase or crossover;<BR/>4. number of patients randomised, excluded, and analysed;<BR/>5. duration, timing, and location of the trial;<BR/>6. source of funding;<BR/>7. type of surgical menopause;<BR/>8. type of intervention and control;<BR/>9. dose regime;<BR/>10. outcomes reported;<BR/>11. how outcomes were defined?<BR/>12. how outcomes were measured?<BR/>13. timing of outcome measurement.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-10-22 17:12:30 +1300" MODIFIED_BY="jane clarke">
<P>The quality of the two included studies (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>; <LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) was adequate with a median Jadad score of 4 <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>
</P>
<P>Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) used computer-generated randomization while for Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) randomization was by means of sealed envelopes with allocation done by a person not connected to the study. Allocation concealment was unclear for Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>). In Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) there was no blinding as the two interventions were different while for Matorras (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) the gynaecologist performing the follow up was kept blinded to the method of intervention. In both studies there were no dropouts and all patients were accounted for. Neither of the two studies declared the funding or sponsorship source nor any conflict of interest.</P>
<P>Statistical analysis was performed in accordance with the guidelines for statistical analysis developed by the Menstrual Disorders and Subfertility Group. Both trials were initially included in one analysis of hormone therapy for post-surgical menopause. Subgroup analysis was not possible as only two papers met the inclusion criteria. Results for each study were expressed as ORs with 95% CIs. Combined meta-analysis with RevMan software was not possible as the two studies used different interventions and controls, nor was statistical heterogeneity testing for the results of the two studies.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-08-21 09:46:56 +1200" MODIFIED_BY="jane clarke">
<P>Two studies fulfilled our inclusion criteria for hormone replacement therapy in patients with endometriosis and post-surgical menopause (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>; <LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>). Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) compared nonstop transdermal application of 17&#946;-estradiol 0.05 mg/day combined with cyclic medroxy progesterone acetate 10 mg/day for 12 days/month with nonstop tibolone 2.5 mg/day in women with a conserved uterus. Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) used sequential administration of estrogen and progesterone following Belchetz's criteria (<LINK REF="REF-Belchetz-1994" TYPE="REFERENCE">Belchetz 1994</LINK>). Two 22 cm<SUP>2</SUP> patches were applied each week to produce a controlled release of 0.05 mg/day. Micronized progesterone was administered orally at a dose of 200 mg/day for 14 days with a 16-day interval free of treatment. This intervention arm was compared to the control group which did not receive treatment.</P>
<P>In Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) the mean follow-up time was 45 months while Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) followed up their participants for only 12 months. The main outcome studied by Matorras et al 2002 was recurrence of endometriosis diagnosed based on histological study, clinical findings, and ultrasound findings suggestive of endometriosis. Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) used pain as the main outcome as reported by the participants at 3, 6, and 12-month follow-up visits after the start of the treatment.</P>
<SUBSECTION>
<HEADING LEVEL="6">Pain and dyspareunia</HEADING>
<P>In Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) the number of women who reported recurrence of pain in the estrogen and progesterone arm was 4/10 compared with 1/11 in the tibolone arm. There was no significant difference between the two groups (OR 6.67, 95% CI 0.60 to 74.51). The wide CI reflects the small sample size in this study.</P>
<P>In Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) the number of patients who reported recurrence of pain was 4/115 in the estrogen with or without progesterone arm compared with 0/57 women in the no-treatment arm. The result was not significant (OR 4.64, 95% CI 0.25 to 87.71).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Confirmed recurrence or exacerbation of endometriosis</HEADING>
<P>While this outcome was not reported in Fedele (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>), Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) found that 2/115 of the estrogen with or without progesterone group developed recurrence of endometriosis that was confirmed histopathologically. No recurrence was reported in the no-treatment group. This finding was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Cancer diagnosis</HEADING>
<P>There was no documentation of cancer formation in either study (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>; <LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Re-operation for endometriosis</HEADING>
<P>In the Matorras study (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) 2/115 women in the estrogen with or without progesterone group were re-operated on while no woman was re-operated in the no-treatment group. The OR was 2.53 (95% CI 0.12 to 53.64) and was not statistically significant.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="6">Mortality</HEADING>
<P>There was no case of mortality related to the medication reported in either study (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>; <LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-08-21 09:47:10 +1200" MODIFIED_BY="jane clarke">
<P>This review addresses the controversial issue of the use of hormone replacement therapy for women with endometriosis and post-surgical menopause. There were only two randomised controlled studies that addressed this issue (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>; <LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>). Although they used similar inclusion criteria (women with endometriosis who underwent bilateral salpingoophorectomy with or without hysterectomy) the reviewed studies used different comparisons; meta-analysis was, therefore, not feasible.<BR/>Both studies have the potential for bias derived from the fact that Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) did not apply blinding to the method of intervention and in Matorras (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) only the gynaecologist following the women was kept unaware about the method of treatment. However, both studies had full retention of participants for the duration of follow up, with regular interim reviews as planned in the methodology. In the analysis, statistical heterogeneity was not tested as the studies used different control interventions. Neither study addressed development of cancer or mortality related to the disease after initiation of the treatment.<BR/>An assessment of pain recurrence after hormone replacement was difficult. In Fedele et al (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>) the pain recurrence was classified as either mild, moderate, or severe while in Matorras (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) there was no such classification. This pain recurrence may be due to the underlying disease of endometriosis and the amount of residual tissue left after the initial surgery, which raises concerns. We considered the recurrence of pelvic pain and dyspareunia as signs of pain recurrence hence this review demonstrates the effect of hormone replacement therapy for women with endometriosis and post-surgical menopause on recurrence of dysmenorrhoea, dyspareunia, and non-menstrual pelvic pain when compared to tibolone and no treatment.<BR/>The recurrence rate of the endometriosis was assessed clinically and by pelvic ultrasonography in Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>). Both studies followed up the women for at least one year (mean of 45 months in Matorras et al (<LINK REF="STD-Matorras2002" TYPE="STUDY">Matorras2002</LINK>) and a minimum of 12 months in Fedele (<LINK REF="STD-Fedele1999" TYPE="STUDY">Fedele1999</LINK>)). There was no significant difference between the hormone replacement groups and the control groups in term of pain recurrence for both studies. As there are only two studies addressing the issue of pain recurrence in women with endometriosis and post-surgical menopause, and both studies have used different control criteria, there is a possibility of publication bias.</P>
<P>In summary there is some evidence from two non-blinded randomised controlled trials that hormone replacement therapy for women with endometriosis and post-surgical menopause may lead to pain and disease recurrence</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-08-21 09:47:10 +1200" MODIFIED_BY="jane clarke">
<IMPLICATIONS_PRACTICE MODIFIED="2008-08-21 09:47:10 +1200" MODIFIED_BY="jane clarke">
<P>Hormone replacement therapy for women with endometriosis and post-surgical menopause could result in pain and disease recurrence. However, the evidence in the literature is not strong enough to suggest depriving severely symptomatic patients from this treatment in order to relieve their menopausal symptoms.<BR/>There is a need for double-blinded randomised controlled studies to investigate further the effects of hormone replacement therapy on disease and pain recurrence.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-08-20 14:15:18 +1200" MODIFIED_BY="[Empty name]">
<P>Further studies are required to compare the use of different types of hormone replacement therapy in women with endometriosis and post surgical menopause. These studies need to address:</P>
<OL>
<LI>recurrence of the disease;</LI>
<LI>recurrence of pain;</LI>
<LI>women's quality of life.</LI>
</OL>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2008-08-20 14:16:07 +1200" MODIFIED_BY="[Empty name]">
<P>We would like to acknowledge National Guard Health Affairs; the Cochrane Menstrual Disorders and Subfertility Review Group; Riyadh, Kingdom of Saudi Arabia for their help and support during the preparation of this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-08-20 14:17:34 +1200" MODIFIED_BY="[Empty name]">
<P>We certify that we have no affiliations or involvement in any organization or entity with a direct financial interest in the subject matter of the review (from, for example, employment, consultancy, stock ownership or honoraria).</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-08-20 14:17:10 +1200" MODIFIED_BY="[Empty name]">
<P>Hanan Al Kadri (HK) and Ali Hajeer (AH) screened titles and abstracts independently. They discarded studies that were not applicable. HK and AH also independently assessed the retrieved abstracts and, when necessary, ordered the full texts of these studies to determine which study satisfied the inclusion criteria.<BR/>The same review authors also carried out data extraction independently. They resolved disagreements in consultation with the other two authors, Samar Hassan (SH) and Haya AlFozan (HF).</P>
<P>SH and HF independently assessed the quality of studies to be included. They resolved discrepancies by discussion with HK and AH. HK wrote the final manuscript and together with AH produced the final review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-08-21 09:48:31 +1200" MODIFIED_BY="jane clarke">
<STUDIES MODIFIED="2008-08-21 09:48:31 +1200" MODIFIED_BY="jane clarke">
<INCLUDED_STUDIES MODIFIED="2008-08-20 14:30:34 +1200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Fedele1999" MODIFIED="2008-08-20 14:28:54 +1200" MODIFIED_BY="[Empty name]" NAME="Fedele1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-20 14:28:54 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fedele L, Bianchi S, Rafaelli R, Zanconato G</AU>
<TI>Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis</TI>
<SO>Maturitas</SO>
<YR>1999</YR>
<VL>32</VL>
<PG>189-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Matorras2002" MODIFIED="2008-08-20 14:30:34 +1200" MODIFIED_BY="[Empty name]" NAME="Matorras2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 14:30:34 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Matorras R, Elorriage MA, Pijoan JI, Ramon O, Rodriguez-Escudero FJ</AU>
<TI>Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who recieved hormone replacement therapy</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>2</NO>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-08-21 09:48:31 +1200" MODIFIED_BY="jane clarke">
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-2004" MODIFIED="2008-08-20 14:31:38 +1200" MODIFIED_BY="[Empty name]" NAME="Alexander 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-20 14:31:38 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JL, Kotz K, Dennerstein L, Kutner SJ, Wallen K, Notelovitz M</AU>
<TI>The effect of postmenopausal hormone therapies on female sexual function: a review of double-blind randomized controlled trials</TI>
<SO>Menopause</SO>
<YR>2004</YR>
<VL>11</VL>
<NO>6 part 2</NO>
<PG>749-65, 786-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arumugam-1998" MODIFIED="2008-08-20 14:32:03 +1200" MODIFIED_BY="[Empty name]" NAME="Arumugam 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-20 14:32:03 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arumugam K, Damodaran P</AU>
<TI>Endometriosis and estrogen replacement therapy</TI>
<SO>Medical Science Research</SO>
<YR>1998</YR>
<VL>26</VL>
<NO>5</NO>
<PG>333-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Attar-2006" MODIFIED="2008-08-20 14:32:41 +1200" MODIFIED_BY="[Empty name]" NAME="Attar 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 14:32:41 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Attar E, Bulun SE</AU>
<TI>Aromatase inhibitors: the next generation of therapeutics for endometriosis?</TI>
<SO>Fertility and Sterility</SO>
<YR>2006</YR>
<VL>85</VL>
<NO>5</NO>
<PG>1307-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bain-2006" MODIFIED="2008-07-10 16:44:40 +1200" MODIFIED_BY="jane clarke" NAME="Bain 2006" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bain C</AU>
<TI>Managing women with a previous diagnosis of endometriosis</TI>
<SO>Journal of the British Menopause Society</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>1</NO>
<PG>28-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barrett_x002d_Connor-2005" MODIFIED="2008-08-20 14:33:27 +1200" MODIFIED_BY="[Empty name]" NAME="Barrett-Connor 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:33:27 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Barrett-Connor E, Grady D, Stefanick ML</AU>
<TI>The rise and fall of menopausal hormone therapy</TI>
<SO>Annual Review of Public Health</SO>
<YR>2005</YR>
<VL>26</VL>
<PG>115-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Beard-1991" MODIFIED="2008-08-20 14:33:52 +1200" MODIFIED_BY="[Empty name]" NAME="Beard 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-08-20 14:33:52 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Beard RW, Kennedy RG, Gangar KF, Stones RW, Rogers V, Reginald PW, Anderson M</AU>
<TI>Bilateral oophorectomy and hysterectomy in the treatment of intractable pelvic pain associated with pelvic congestion</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1991</YR>
<VL>98</VL>
<NO>10</NO>
<PG>988-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bianchi-1997" MODIFIED="2008-08-21 09:41:23 +1200" MODIFIED_BY="jane clarke" NAME="Bianchi 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-21 09:41:23 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bianchi S, Raffaelli R, Borruto F, Agnoli B, Fedele L</AU>
<TI>Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with residual pelvic endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>1997</VL>
<PG>187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradshaw-2002" MODIFIED="2008-08-21 09:43:11 +1200" MODIFIED_BY="jane clarke" NAME="Bradshaw 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-21 09:43:11 +1200" MODIFIED_BY="jane clarke" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradshaw H</AU>
<TI>Estrogen replacement reverses ovariectomy-induced vaginal hyperalgesia in the rat</TI>
<SO>Maturitas</SO>
<YR>2002</YR>
<VL>41</VL>
<NO>2</NO>
<PG>157-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bulum-2005" MODIFIED="2008-08-20 14:37:43 +1200" MODIFIED_BY="[Empty name]" NAME="Bulum 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:37:43 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B,Tamura M, Lin Z</AU>
<TI>Aromataz in endometriosis and uterine leiomyomata</TI>
<SO>Journal of Steroid Biochemistry and Molecular Biology</SO>
<YR>2005</YR>
<VL>95</VL>
<NO>1-5</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chalas-2005" MODIFIED="2008-08-20 14:38:51 +1200" MODIFIED_BY="[Empty name]" NAME="Chalas 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:38:51 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD</AU>
<TI>Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>192</VL>
<NO>4</NO>
<PG>1230-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Colau-2007" MODIFIED="2008-08-20 14:39:28 +1200" MODIFIED_BY="[Empty name]" NAME="Colau 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-20 14:39:28 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Colau JC</AU>
<TI>The genitourinary disorders of the menopause. Role of hormonal treatment</TI>
<SO>Reproduction Humaine et Hormones</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>5</NO>
<PG>300-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2003" MODIFIED="2008-08-20 14:39:58 +1200" MODIFIED_BY="[Empty name]" NAME="Davis 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 14:39:58 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis CJ, McMillan L</AU>
<TI>Pain in endometriosis: Effectiveness of medical and surgical management</TI>
<SO>Current Opinion in Obstetrics and Gynecology</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>6</NO>
<PG>507-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dennerstein-1980" NAME="Dennerstein 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dennerstein L, Burrows GD, Hyman GJ, Sharpe K</AU>
<TI>Some clinical effects of oestrogen and progestogen</TI>
<SO>Maturitas</SO>
<YR>1980</YR>
<VL>2</VL>
<NO>1</NO>
<PG>19-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dowsett-2005" MODIFIED="2008-08-20 14:41:04 +1200" MODIFIED_BY="[Empty name]" NAME="Dowsett 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:41:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dowsett M, Folkerd E, Doody D, Haynes B</AU>
<TI>The biology of steroid hormones and endocrine treatment of breast cancer</TI>
<SO>Breast</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>6</NO>
<PG>452-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farquhar-2006" MODIFIED="2008-08-20 14:40:41 +1200" MODIFIED_BY="[Empty name]" NAME="Farquhar 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 14:40:41 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Farquhar C, Latthe P</AU>
<TI>Chronic pelvic pain: Aetiology and therapy</TI>
<SO>Review in Gynaecological and Perinatal Practice</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>3-4</NO>
<PG>117-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fedele-2005" MODIFIED="2008-08-20 14:41:37 +1200" MODIFIED_BY="[Empty name]" NAME="Fedele 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:41:37 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fedele L, Bianchi S, Zanconato G, Berlanda N, Borruto F, Frontino G</AU>
<TI>Tailoring radicality in demolitive surgery for deeply infiltrating endometriosis</TI>
<SO>American Journal Of Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>193</VL>
<NO>1</NO>
<PG>114-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frackiewicz-2003" MODIFIED="2008-08-20 14:42:04 +1200" MODIFIED_BY="[Empty name]" NAME="Frackiewicz 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 14:42:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frackiewicz EJ, Zarotsky V</AU>
<TI>Diagnosis and treatment of endometriosis</TI>
<SO>Expert Opinion on Pharmacotherapy</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>67-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedlander-2002" MODIFIED="2008-08-20 14:42:55 +1200" MODIFIED_BY="[Empty name]" NAME="Friedlander 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 14:42:55 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedlander AH</AU>
<TI>Dentistry &amp; medicine. The physiology, medical management and oral implications of menopause</TI>
<SO>Journal of the American Dental Association</SO>
<YR>2002</YR>
<VL>133</VL>
<NO>1</NO>
<PG>73-81, 89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghezzi-2005" MODIFIED="2008-08-20 14:43:41 +1200" MODIFIED_BY="[Empty name]" NAME="Ghezzi 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 14:43:41 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ghezzi F, Cromi A, Colombo G, Uccella S, Bergamini V, Serati M</AU>
<TI>Minimizing ancillary ports size in gynecologic laparoscopy: A randomized trial</TI>
<SO>Journal of Minimally Invasive Gynecology</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>6</NO>
<PG>480-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goulding-1991" MODIFIED="2008-08-20 14:44:51 +1200" MODIFIED_BY="[Empty name]" NAME="Goulding 1991" YEAR="1991">
<REFERENCE MODIFIED="2008-08-20 14:44:51 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goulding A, Fisher L</AU>
<TI>Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat</TI>
<SO>Journal of Bone and Mineral Research</SO>
<YR>1991</YR>
<VL>6</VL>
<NO>11</NO>
<PG>1177-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Graziottin-2007" MODIFIED="2008-08-20 14:45:16 +1200" MODIFIED_BY="[Empty name]" NAME="Graziottin 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-20 14:45:16 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Graziottin A</AU>
<TI>Effect of primary menopause on sexuality</TI>
<SO>Women's Health</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>4</NO>
<PG>455-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hackman-1997" MODIFIED="2008-08-20 14:50:31 +1200" MODIFIED_BY="[Empty name]" NAME="Hackman 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-20 14:50:31 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hackman BW, Galbraith D</AU>
<TI>Six months pilot study of oestrogen replacement therapy with piperazine oestrone sulphate and its effect on memory</TI>
<SO>Current Medical Research and Opinion</SO>
<YR>1997</YR>
<VL>4</VL>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-2006" MODIFIED="2008-08-20 14:52:24 +1200" MODIFIED_BY="[Empty name]" NAME="Hansen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 14:52:24 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen KA, Eyster KM</AU>
<TI>A review of current management of endometriosis in 2006: an evidence-based approach</TI>
<SO>South Dakota Medicine: The Journal of the South Dakota State Medical Association</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>4</NO>
<PG>153-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holub-2000" MODIFIED="2008-08-20 14:55:58 +1200" MODIFIED_BY="[Empty name]" NAME="Holub 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-20 14:55:58 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Holub Z, Voracek J, Wagnerova M, Kliment L</AU>
<TI>Hormone replacement therapy in women with surgical treatment of endometriosis and adenomyosis: prospective and follow-up study. part I</TI>
<TO>Hormonalni substitucni lecba u zen operovanych pro endometriozu a adenomyozu: prospektivni follow-up studie. I. Cast</TO>
<SO>Ceskoslovenska Gynekologie/Ceska lekarska spolecnost J Ev Purkyne</SO>
<YR>2000</YR>
<VL>65</VL>
<NO>1</NO>
<PG>16-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Holub-2001" MODIFIED="2008-08-20 14:56:55 +1200" MODIFIED_BY="[Empty name]" NAME="Holub 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-20 14:56:55 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Holub Z, Brozkova H, Kucera M, Krackova J, Martinovska M, Muller M, et al</AU>
<TI>Hormonal substitution treatment in women operated on account of endometriosis and adenomyosis: Prospective follow-up study (part II).</TI>
<TO>Hormonalni substitucni lecba u zen operovanych pro endometriozu a adenomyozu - prospektivni follow-up studie (II. cast).</TO>
<SO>Ceskoslovenska Gynekologie</SO>
<YR>2001</YR>
<VL>66</VL>
<NO>6</NO>
<PG>405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-W_x002d_P-2006" MODIFIED="2008-08-20 14:58:25 +1200" MODIFIED_BY="[Empty name]" NAME="Hu W-P 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 14:58:25 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu W-P, Sun KT, Zhao Y</AU>
<TI>Endometriosis-specific genes identified by real-time reverse transcription-polymerase chain reaction expression profiling of endometriosis versus autologous uterine endometrium</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2006</YR>
<VL>91</VL>
<NO>1</NO>
<PG>228-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivanov-1998" MODIFIED="2008-07-10 16:46:33 +1200" MODIFIED_BY="jane clarke" NAME="Ivanov 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivanov S, Ivanov S</AU>
<TI>Malignant degeneration in women operated on for endometriosis</TI>
<SO>Akusherstvo i Ginekologiia</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>3</NO>
<PG>29-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jelovsek-2004" MODIFIED="2008-08-20 14:59:08 +1200" MODIFIED_BY="[Empty name]" NAME="Jelovsek 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-20 14:59:08 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jelovsek JE, Winans C, Brainard J, Falcon T</AU>
<TI>Endometriosis of the liver containing mullerian adenosarcoma: case report</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2004</YR>
<VL>191</VL>
<NO>5</NO>
<PG>1725-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2006" MODIFIED="2008-07-14 01:48:12 +1200" MODIFIED_BY="[Empty name]" NAME="Johnson 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-07-14 01:48:12 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson N</AU>
<TI>Management of dysmenorrhea</TI>
<SO>Reviews in Gynaecological and Perinatal Practice.</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>1-2</NO>
<PG>57-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2002" MODIFIED="2008-08-20 15:01:03 +1200" MODIFIED_BY="[Empty name]" NAME="Jones 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:01:03 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones KD, Owen E, Berresford A, Sutton C</AU>
<TI>Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon</TI>
<SO>Gynecologic Oncology</SO>
<YR>2002</YR>
<VL>86</VL>
<NO>2</NO>
<PG>220-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jordan-2003" MODIFIED="2008-08-20 14:59:44 +1200" MODIFIED_BY="[Empty name]" NAME="Jordan 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 14:59:44 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jordan SJ, Purdie DM, Whiteman DC, Webb PM</AU>
<TI>Risk factors for epithelial ovarian cancer</TI>
<SO>Cancer Forum</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>148-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kenemans-2005" MODIFIED="2008-08-20 15:00:17 +1200" MODIFIED_BY="[Empty name]" NAME="Kenemans 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 15:00:17 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kenemans P, Speroff L</AU>
<TI>Tibolone: Clinical recommendations and practical guidelines: A report of the International Tibolone Consensus Group</TI>
<SO>Maturitas</SO>
<YR>2005</YR>
<VL>51</VL>
<NO>1</NO>
<PG>21-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khastgir-1998" MODIFIED="2008-08-20 15:01:38 +1200" MODIFIED_BY="[Empty name]" NAME="Khastgir 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-08-20 15:01:38 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khastgir G</AU>
<TI>Hysterectomy, ovarian failure and depression</TI>
<SO>Menopause</SO>
<YR>1998</YR>
<VL>5</VL>
<NO>2</NO>
<PG>113-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiesel-2002" MODIFIED="2008-08-20 15:02:11 +1200" MODIFIED_BY="[Empty name]" NAME="Kiesel 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:02:11 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiesel LA, Rody A, Greb RR, Szilagyi A</AU>
<TI>Clinical use of GnRh analogues</TI>
<SO>Clinical Endocrinology</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>6</NO>
<PG>677-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kitawaki-2001" MODIFIED="2008-08-20 15:03:06 +1200" MODIFIED_BY="[Empty name]" NAME="Kitawaki 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-20 15:03:06 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kitawaki J, Obayashi H, Ishihara H, Koshiba H, Kusuki I, Kado N, et al</AU>
<TI>Estrogen receptor-alpha gene polymorphism is associated with endometriosis, adenomyosis and leiomyomata</TI>
<SO>Human Reproduction</SO>
<YR>2001</YR>
<VL>16</VL>
<NO>1</NO>
<PG>51-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kouides-2006" MODIFIED="2008-08-20 15:03:43 +1200" MODIFIED_BY="[Empty name]" NAME="Kouides 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:03:43 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kouides PA</AU>
<TI>Current understanding of von Willebrand's disease in women - Some answers, more questions</TI>
<SO>Haemophilia</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>3</NO>
<PG>143-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kroon-2005" MODIFIED="2008-08-20 15:05:27 +1200" MODIFIED_BY="[Empty name]" NAME="Kroon 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 15:05:27 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kroon N, Reginald P</AU>
<TI>Medical management of chronic pelvic pain</TI>
<SO>Current Obstetrics and Gynaecology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuenzel-2006" MODIFIED="2008-08-20 15:06:03 +1200" MODIFIED_BY="[Empty name]" NAME="Kuenzel 2006" YEAR="">
<REFERENCE MODIFIED="2008-08-20 15:06:03 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuenzel W</AU>
<TI>Editors' highlights</TI>
<SO>European Journal of Obstetrics and Gynecology</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>2</NO>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuohung-2002" MODIFIED="2008-08-20 15:07:46 +1200" MODIFIED_BY="[Empty name]" NAME="Kuohung 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:07:46 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuohung W, Jones GL, Vitonis AF, Cramer DW, Kennedy SH, Thomas D, Hornstein MD</AU>
<TI>Characteristics of patients with endometriosis in the United States and the United Kingdom</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>78</VL>
<NO>4</NO>
<PG>767-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuzel-1999" MODIFIED="2008-08-20 15:08:18 +1200" MODIFIED_BY="[Empty name]" NAME="Kuzel 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-20 15:08:18 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kuzel D, Fucikova Z, Toth D, Cibula D, Zivny J</AU>
<TI>Endometrial ablasion: prospective 3-year follow-up study</TI>
<SO>Ceskoslovaska Gynekologic</SO>
<YR>1999</YR>
<VL>64</VL>
<NO>2</NO>
<PG>87-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lalchandani-2005" MODIFIED="2008-08-20 15:06:26 +1200" MODIFIED_BY="[Empty name]" NAME="Lalchandani 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 15:06:26 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lalchandani S, Baxter A, Philips K</AU>
<TI>Is helium thermal coagulator therapy for the treatment of women with minimal to moderate endometriosis cost-effective? prospective randomised controlled trial</TI>
<SO>Gynecological Surgery</SO>
<YR>2005</YR>
<VL>2</VL>
<NO>4</NO>
<PG>255-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leyendecker-2002" MODIFIED="2008-08-20 15:06:46 +1200" MODIFIED_BY="[Empty name]" NAME="Leyendecker 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:06:46 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leyendecker G, Herbertz M, Kunz G, Mall G</AU>
<TI>Endometriosis results from the dislocation of basal endometrium</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>10</NO>
<PG>2725-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobo-1984" MODIFIED="2008-08-20 15:10:25 +1200" MODIFIED_BY="[Empty name]" NAME="Lobo 1984" YEAR="1984">
<REFERENCE MODIFIED="2008-08-20 15:10:25 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lobo RA, McCormick W, Singer F, Roy S</AU>
<TI>Depo-Medroxyprogesterone acetate compared with conjugated estrogens for the treatment of post menopausal woman</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1984</YR>
<VL>63</VL>
<NO>1</NO>
<PG>1-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loizzi-2005" MODIFIED="2008-08-20 15:11:08 +1200" MODIFIED_BY="[Empty name]" NAME="Loizzi 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 15:11:08 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loizzi V, Cormio G, Vicino M, Fattizzi N, Bettocchi S, Selvaggi L</AU>
<TI>Hormone replacement therapy on ovarian and uterine cancer risk and cancer survivors: How shall we do no harm?</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>3</NO>
<PG>420-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Long-2006" MODIFIED="2008-08-20 15:11:36 +1200" MODIFIED_BY="[Empty name]" NAME="Long 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:11:36 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM</AU>
<TI>A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women</TI>
<SO>Menopause</SO>
<YR>2006</YR>
<VL>13</VL>
<NO>5</NO>
<PG>737-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lopez_x002d_Olmos-2003" MODIFIED="2008-08-20 15:12:05 +1200" MODIFIED_BY="[Empty name]" NAME="Lopez-Olmos 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 15:12:05 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lopez-Olmos J</AU>
<TI>Sexuality following the menopause: The influence of hormone replacement therapy on women with sexual dysfunction</TI>
<SO>Clinica e Investigacion en Ginecologia y Obstetricia</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>7</NO>
<PG>212-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lu-1995" MODIFIED="2008-08-20 15:12:43 +1200" MODIFIED_BY="[Empty name]" NAME="Lu 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-20 15:12:43 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lu PY, Ory SJ</AU>
<TI>Endometriosis: current management</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1995</YR>
<VL>70</VL>
<NO>5</NO>
<PG>453-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luciano-2006" MODIFIED="2008-08-20 15:27:14 +1200" MODIFIED_BY="[Empty name]" NAME="Luciano 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:27:14 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luciano DE, Luciano AA</AU>
<TI>Pain associated with endometriosis: Therapeutic options</TI>
<SO>Women's Health</SO>
<YR>2006</YR>
<VL>2</VL>
<NO>4</NO>
<PG>617-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mannix-2004" MODIFIED="2008-08-20 15:27:50 +1200" MODIFIED_BY="[Empty name]" NAME="Mannix 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-20 15:27:50 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mannix LK, Calhoun AH</AU>
<TI>Menstrual migraine</TI>
<SO>Current Treatment Options in Neurology</SO>
<YR>2004</YR>
<VL>6</VL>
<NO>6</NO>
<PG>489-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendoza-2000" MODIFIED="2008-08-20 15:28:25 +1200" MODIFIED_BY="[Empty name]" NAME="Mendoza 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-20 15:28:25 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Menodza N, Suarez AM, Alamo F, Bartual E, Vergara F, Herruzo A</AU>
<TI>Lipid effects, effectiveness and acceptability of tibolone versus transdermic 17beta-estradiol for hormonal replacement therapy in women with surgical menopause</TI>
<SO>Maturitas</SO>
<YR>2000</YR>
<VL>37</VL>
<NO>1</NO>
<PG>37-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mizutani-1995" MODIFIED="2008-08-20 15:29:17 +1200" MODIFIED_BY="[Empty name]" NAME="Mizutani 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-20 15:29:17 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mizutani T, Nishiyama S, Amakawa I, Watanabe A, Nakamuro K, Terada N</AU>
<TI>Danazol concentrations in ovary, uterus, serum and their effect on the hypothalamic-pituitary-ovarian axis during vaginal administration of a danazol suppository</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>6</NO>
<PG>1184-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modugno-2003" MODIFIED="2008-08-20 15:29:56 +1200" MODIFIED_BY="[Empty name]" NAME="Modugno 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 15:29:56 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modugno F, Boyd J, Baum A, Bigbee WL, Cramer D, Ferrell R, et al</AU>
<TI>Ovarian cancer and high risk women - implications for prevention, screening and early detection</TI>
<SO>Gynecologic Oncology</SO>
<YR>2003</YR>
<VL>91</VL>
<NO>1</NO>
<PG>15-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moen-2002" MODIFIED="2008-08-20 15:32:11 +1200" MODIFIED_BY="[Empty name]" NAME="Moen 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:32:11 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moen MH, Stokstad T</AU>
<TI>A long term follow-up study of women with symptomatic endometriosis diagnosed incidently at sterilization</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>78</VL>
<NO>4</NO>
<PG>773-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morini-1993" MODIFIED="2008-07-10 16:48:44 +1200" MODIFIED_BY="jane clarke" NAME="Morini 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morini A, Aleandri V, Cantonetti G, Benagiano G</AU>
<TI>Directions of future research on GnGh analogs in the treatment of endometriosis and uterine fibromyoma</TI>
<SO>Minerva Ginecologica</SO>
<YR>1993</YR>
<VL>45</VL>
<NO>10</NO>
<PG>455-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mousa-2007" MODIFIED="2008-08-20 15:32:55 +1200" MODIFIED_BY="[Empty name]" NAME="Mousa 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-20 15:32:55 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mousa NA, Bedaiwy MA, Casper RF</AU>
<TI>Aromatase inhibitors in the treatment of severe endometriosis</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>109</VL>
<NO>6</NO>
<PG>1421-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murphy-1995" MODIFIED="2008-08-20 15:33:40 +1200" MODIFIED_BY="[Empty name]" NAME="Murphy 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-20 15:33:40 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murphy AA, Kettle LM, Morales AJ, Roberts V, Parmley T, Yen SS</AU>
<TI>Endometrial effects of long-term low-dose administration of RU486</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>63</VL>
<NO>4</NO>
<PG>76</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagao-2006" MODIFIED="2008-08-20 15:35:36 +1200" MODIFIED_BY="[Empty name]" NAME="Nagao 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:35:36 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagao S, Fujiwara K, Ishikawa H, Oda T, Tanaka K, Aotani E, Kohano I</AU>
<TI>Hormonal function after ovarian transposition to the abdominal subcutaneous fat tissue</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>1</NO>
<PG>121-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nagata-2001" MODIFIED="2008-08-20 15:36:39 +1200" MODIFIED_BY="[Empty name]" NAME="Nagata 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-20 15:36:39 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nagata C, Takatsuka N, Kawakami N, Shimizu H</AU>
<TI>Soy product intake and premenopausal hysterectomy in a follow-up study of a Japanese women</TI>
<SO>European Journal of Clinical Nutrition</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>9</NO>
<PG>773-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Namnoum-1995" MODIFIED="2008-08-20 15:37:30 +1200" MODIFIED_BY="[Empty name]" NAME="Namnoum 1995" YEAR="1995">
<REFERENCE MODIFIED="2008-08-20 15:37:30 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Namnoum AB, Hickman TN, Goodman SB, Gehbach DL, Rock JA</AU>
<TI>Incidence of symptom recurrence after hysterectomy for endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>5</NO>
<PG>898-902</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nappi-2006" MODIFIED="2008-08-20 15:38:53 +1200" MODIFIED_BY="[Empty name]" NAME="Nappi 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:38:53 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nappi R, Wawra K, Schmitt S</AU>
<TI>Hypoactive sexual desire disorder in post menopausal women</TI>
<SO>Gynecological Endocrinology</SO>
<YR>2006</YR>
<VL>22</VL>
<NO>6</NO>
<PG>318-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasir-2004" MODIFIED="2008-08-20 15:39:32 +1200" MODIFIED_BY="[Empty name]" NAME="Nasir 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-20 15:39:32 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nasir L, Bope ET</AU>
<TI>Management of pelvic pain from dysmenorrhea or endometriosis</TI>
<SO>Journal of the American Board of Family Practice</SO>
<YR>2004</YR>
<VL>17</VL>
<NO>1</NO>
<PG>43-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Noble-1979" MODIFIED="2008-08-20 15:40:04 +1200" MODIFIED_BY="[Empty name]" NAME="Noble 1979" YEAR="1979">
<REFERENCE MODIFIED="2008-08-20 15:40:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nobel AD, Letchworth AT</AU>
<TI>Medical treatment of endometriosis: A comparative trial</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1979</YR>
<VL>55</VL>
<NO>5</NO>
<PG>37-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozawa-2006" MODIFIED="2008-08-20 15:40:51 +1200" MODIFIED_BY="[Empty name]" NAME="Ozawa 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:40:51 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ozawa Y, Murakami T, Terada Y, Yaegashi N, Okamura K, Kuriyama S, Tsuji I</AU>
<TI>Management of pain associated with endometriosis: An update of the painful problems</TI>
<SO>Tohoku Journal of Experimental Medicine</SO>
<YR>2006</YR>
<VL>210</VL>
<NO>3</NO>
<PG>175-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ozols-2004" MODIFIED="2008-08-20 15:41:32 +1200" MODIFIED_BY="[Empty name]" NAME="Ozols 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-08-20 15:41:32 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ozols RF, Bookman MA, Connoly DC, Daly MB, Godwin AK, Schilder RJ, et al</AU>
<TI>Focus in epithelial ovarian cancer</TI>
<SO>Cancer Cell</SO>
<YR>2003</YR>
<VL>5</VL>
<NO>1</NO>
<PG>19-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-1996" MODIFIED="2008-08-20 15:42:55 +1200" MODIFIED_BY="[Empty name]" NAME="Perry 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-20 15:42:55 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry CM, Brogden RN</AU>
<TI>Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders</TI>
<SO>Drugs</SO>
<YR>1996</YR>
<VL>51</VL>
<NO>2</NO>
<PG>319-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piltonen-2002" MODIFIED="2008-08-20 15:43:47 +1200" MODIFIED_BY="[Empty name]" NAME="Piltonen 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-08-20 15:43:47 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piltonen T, Koivunen R, Morin-Papunen L, Ruokonen A, Huhtaniemi IT, Tapanainen JS</AU>
<TI>Ovarian and adrenal steroid production: Regulatory role of LH/HCG</TI>
<SO>Human Reproduction</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>3</NO>
<PG>620-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pruthi-2007" MODIFIED="2008-08-20 15:44:17 +1200" MODIFIED_BY="[Empty name]" NAME="Pruthi 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-20 15:44:17 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pruthi S, Brandt KR, Degnim AC, Goetz MP, Perez EA, Reynolds CA, et al</AU>
<TI>A multidisplinary approach to the management of breast cancer, part 1: Prevention and diagnosis</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2007</YR>
<VL>82</VL>
<NO>8</NO>
<PG>999-1012</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Purdie-1999" MODIFIED="2008-08-20 15:45:04 +1200" MODIFIED_BY="[Empty name]" NAME="Purdie 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-20 15:45:04 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, et al</AU>
<TI>Hormone replacement therapy and risk of epithelial ovarian cancer</TI>
<SO>British Journal of Cancer</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>3</NO>
<PG>559-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rattanachaiyanont-03" MODIFIED="2008-08-20 15:45:47 +1200" MODIFIED_BY="[Empty name]" NAME="Rattanachaiyanont 03" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 15:45:47 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rattanachaiyanont M, Angsuwatthana S, Inthawiwat S, Tanmahasamut P, Techatraisak K, Leerasiri P</AU>
<TI>Hormonal replacement therapy in surgical menopause with underlying endometriosis</TI>
<SO>Journal of the Medical Association of Thailand</SO>
<YR>2003</YR>
<VL>86</VL>
<NO>8</NO>
<PG>702-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rees-2006" MODIFIED="2008-08-20 15:46:10 +1200" MODIFIED_BY="[Empty name]" NAME="Rees 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:46:10 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rees M</AU>
<TI>Gynecological oncology prospective on management of the menopause</TI>
<SO>European Journal of Surgical Oncology</SO>
<YR>2006</YR>
<VL>32</VL>
<NO>8</NO>
<PG>892-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reid-1996" MODIFIED="2008-08-20 15:46:53 +1200" MODIFIED_BY="[Empty name]" NAME="Reid 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-08-20 15:46:53 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reid BA, Gangar KF, Rogers V, Thomas E, Beard RW</AU>
<TI>Long-term results of bilateral oophorectomy for the treatment of chronic pelvic pain: Relief of pain and special hormone replacement therapy requirements</TI>
<SO>Journal of Obstetrics and Gynecology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>6</NO>
<PG>538-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robson-2003" MODIFIED="2008-08-20 15:47:36 +1200" MODIFIED_BY="[Empty name]" NAME="Robson 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 15:47:36 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, Offit K</AU>
<TI>Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy</TI>
<SO>Gynecologic Oncology</SO>
<YR>2003</YR>
<VL>89</VL>
<NO>2</NO>
<PG>281-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roman-2007" MODIFIED="2008-08-20 15:47:59 +1200" MODIFIED_BY="[Empty name]" NAME="Roman 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-08-20 15:47:59 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roman H</AU>
<TI>Guidelines for the management of painful endometriosis</TI>
<SO>Journal de Gynecologie Obstetrique et Biologie de la Reproduction</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>2</NO>
<PG>141-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotella-2006" MODIFIED="2008-08-20 15:49:52 +1200" MODIFIED_BY="[Empty name]" NAME="Rotella 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:49:52 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rotella D</AU>
<TI>COMP - structure-based design and development of estrogen receptor</TI>
<SO>IDrugs</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>11</NO>
<PG>748-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-Gonzalez-2001" MODIFIED="2008-08-20 15:50:35 +1200" MODIFIED_BY="[Empty name]" NAME="Santos Gonzalez 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-20 15:50:35 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos Gonzalez JE</AU>
<TI>Treatment of early menopause</TI>
<SO>Revisita de Iberoamericana de Revisiones en Menopausia</SO>
<YR>2001</YR>
<VL>3</VL>
<NO>2</NO>
<PG>15-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schor-1999" MODIFIED="2008-08-20 15:51:27 +1200" MODIFIED_BY="[Empty name]" NAME="Schor 1999" YEAR="1999">
<REFERENCE MODIFIED="2008-08-20 15:51:27 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schor E, Barakat EC, Simoes MJ, De Freitas V, Giannotti Filho O, Rodrigues De Lima G</AU>
<TI>Effects of conjugated estrogens and progestogen in surgically induced endometriosis in oophorectomized rats</TI>
<SO>Clnical and Experimental Obstetrics and Gynecology</SO>
<YR>1999</YR>
<VL>26</VL>
<NO>3-4</NO>
<PG>158-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwenkhagen-2006" MODIFIED="2008-08-20 15:52:03 +1200" MODIFIED_BY="[Empty name]" NAME="Schwenkhagen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:52:03 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwenkhagen A</AU>
<TI>When libido stops</TI>
<SO>MMW Fortschritte der Medizin</SO>
<YR>2006</YR>
<VL>148</VL>
<NO>25</NO>
<PG>54-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Setnikar-1997" MODIFIED="2008-08-20 15:54:50 +1200" MODIFIED_BY="[Empty name]" NAME="Setnikar 1997" YEAR="1997">
<REFERENCE MODIFIED="2008-08-20 15:54:50 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sitnikar I, Rovati LC, Thebault JJ, Guillaume M, Mignot A, Renoux A, Gualano V</AU>
<TI>Pharmacokinetics of estradiol and of estrone during application of three strengths of an estradiol transdermal patch with active matrix</TI>
<SO>Arzneimittel-Forschung/Drug Research</SO>
<YR>1997</YR>
<VL>47</VL>
<NO>7</NO>
<PG>859-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tan-2008" MODIFIED="2008-08-21 09:48:31 +1200" MODIFIED_BY="jane clarke" NAME="Tan 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-08-21 09:48:31 +1200" MODIFIED_BY="jane clarke" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tan SH, Wolff AC</AU>
<SO>Current Oncology Reports</SO>
<YR>2008</YR>
<VL>10</VL>
<NO>1</NO>
<PG>27-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tietjen-2006" MODIFIED="2008-08-20 15:57:14 +1200" MODIFIED_BY="[Empty name]" NAME="Tietjen 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:57:14 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tietjen GE, Conway A, Utley C, Gunning WT, Herial NA</AU>
<TI>Migraine is associated with menorrhagia and endometriosis</TI>
<SO>Headache</SO>
<YR>2006</YR>
<VL>46</VL>
<NO>3</NO>
<PG>422-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tok-2006" MODIFIED="2008-08-20 15:58:07 +1200" MODIFIED_BY="[Empty name]" NAME="Tok 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 15:58:07 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tok EC, Ertunc D, Tataroglu C, Yazici G, Kanat H, Dilek S</AU>
<TI>Clinicopathologic study of gynecological cancer</TI>
<SO>International Journal of Gynecological Cancer</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>2</NO>
<PG>501-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Uemura-2000" MODIFIED="2008-08-20 15:59:34 +1200" MODIFIED_BY="[Empty name]" NAME="Uemura 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-08-20 15:59:34 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Uemura H, Irahara M, Yoneda N, Yasui T, Genjida K, Miyamoto KL, et al</AU>
<TI>Close correlation between estrogen treatment and renal phosphate reabsorption capacity</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>2000</YR>
<VL>85</VL>
<NO>3</NO>
<PG>1215-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Usman-2008" MODIFIED="2008-08-20 16:00:21 +1200" MODIFIED_BY="[Empty name]" NAME="Usman 2008" YEAR="2008">
<REFERENCE MODIFIED="2008-08-20 16:00:21 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Usman SB, Indusekhar R, O' Brien S</AU>
<TI>Hormonal management of premenstrual syndrome</TI>
<SO>Best Practice and Research in Clinical Obstetrics and Gynaecology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2</NO>
<PG>251-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Varma-2006" MODIFIED="2008-08-20 16:01:21 +1200" MODIFIED_BY="[Empty name]" NAME="Varma 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 16:01:21 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Varma R, Sinha D, Gupta JK</AU>
<TI>Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS) - A systematic enquiry and overview</TI>
<SO>European Journal of Obstetrics, Gynecology, and Reproductive Biology</SO>
<YR>2006</YR>
<VL>125</VL>
<NO>1</NO>
<PG>9-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Velasco-2006" MODIFIED="2008-08-20 16:01:58 +1200" MODIFIED_BY="[Empty name]" NAME="Velasco 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 16:01:58 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Velasco I, Rueda J, Acien P</AU>
<TI>Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis</TI>
<SO>Molecular Human Reproduction</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>6</NO>
<PG>377-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vercellini-2008" NAME="Vercellini 2008" YEAR="2008">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vercellini P, Somigliana E, Vigano P, Abbiati A, Daguati R</AU>
<TI>Endometriosis: current and future medical therapies</TI>
<SO>Best Practice and Research in Clinical Obstetrics and Gynaecology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>2</NO>
<PG>275-306</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-2005" MODIFIED="2008-08-20 16:02:29 +1200" MODIFIED_BY="[Empty name]" NAME="Walker 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-08-20 16:02:29 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker ID</AU>
<TI>Hormone replacement therapy and venous thrombolism</TI>
<SO>Thrombosis Research</SO>
<YR>2005</YR>
<VL>115</VL>
<PG>88-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weiss-1982" MODIFIED="2008-08-20 16:05:16 +1200" MODIFIED_BY="[Empty name]" NAME="Weiss 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-08-20 16:05:16 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Weiss NS, Lyon JL, Krishnamurthy S, Dietert SE, Liff JM, Daling JR</AU>
<TI>Noncontraceptive estrogen use and the occurance of ovarian cancer</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1982</YR>
<VL>68</VL>
<NO>1</NO>
<PG>95-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winkel-2001" MODIFIED="2008-08-20 16:06:38 +1200" MODIFIED_BY="[Empty name]" NAME="Winkel 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-08-20 16:06:38 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winkel CA, Scialli AR</AU>
<TI>Medical and surgical therapies for pain associated with endometriosis</TI>
<SO>Journal of Women Health &amp; Gender-Based Medicine</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>2</NO>
<PG>137-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-1982" MODIFIED="2008-08-20 16:06:57 +1200" MODIFIED_BY="[Empty name]" NAME="Wolff 1982" YEAR="1982">
<REFERENCE MODIFIED="2008-08-20 16:06:57 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wolff JP, Cachelou R, Gueritee N</AU>
<TI>Absence of systematic hormonal effects in an oestradiol diether topically active on the vaginal mucosa</TI>
<SO>Maturitas</SO>
<YR>1982</YR>
<VL>4</VL>
<NO>4</NO>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wolff-1983" MODIFIED="2008-08-20 16:09:13 +1200" MODIFIED_BY="[Empty name]" NAME="Wolff 1983" YEAR="1983">
<REFERENCE MODIFIED="2008-08-20 16:09:13 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wolff JP, Cachelou R</AU>
<TI>Sexual problems secondary to gynaecological cancer. Their local treatment by an estradiol diether deviod of systemic hormonal activity</TI>
<SO>Revue Francaise de Gynecologie et d'Obstetrique</SO>
<YR>1983</YR>
<VL>78</VL>
<NO>3</NO>
<PG>189-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wylie-2006" MODIFIED="2008-08-20 16:09:38 +1200" MODIFIED_BY="[Empty name]" NAME="Wylie 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-08-20 16:09:38 +1200" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wylie KR</AU>
<TI>Sexuality and the menopause</TI>
<SO>Journal of the British Menopause Society</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>149-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yohannes-2003" MODIFIED="2008-08-20 16:09:56 +1200" MODIFIED_BY="[Empty name]" NAME="Yohannes 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-08-20 16:09:56 +1200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yohannes P</AU>
<TI>Ureteral endometriosis</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>170</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-08-20 16:28:51 +1200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-08-20 16:28:51 +1200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Agarwal-2002" MODIFIED="2008-08-20 16:11:15 +1200" MODIFIED_BY="[Empty name]" NAME="Agarwal 2002" TYPE="JOURNAL_ARTICLE">
<AU>Agarwal SK</AU>
<TI>Impact of six months of GnRH agonist therapy for endometriosis. Is there an age-related effect on bone mineral density?</TI>
<SO>The Journal of Reproductive Medicine</SO>
<YR>2002</YR>
<VL>47</VL>
<NO>7</NO>
<PG>530-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Belchetz-1994" MODIFIED="2008-08-20 16:15:44 +1200" MODIFIED_BY="[Empty name]" NAME="Belchetz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Belchetz PE</AU>
<TI>Hormonal treatment of postmenopausal women</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<NO>15</NO>
<PG>1062-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruner_x002d_Tran-2002" MODIFIED="2008-07-13 16:46:03 +1200" MODIFIED_BY="[Empty name]" NAME="Bruner-Tran 2002" TYPE="JOURNAL_ARTICLE">
<AU>Bruner-Tran KL, Webster-Clair D, Osteen KG</AU>
<TI>Experimental endometriosis: the nude mouse as a xenographic host</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>2002</YR>
<VL>955</VL>
<PG>328-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cedars-1990" NAME="Cedars 1990" TYPE="JOURNAL_ARTICLE">
<AU>Cedars M, Lu J, Meldrum D, Judd H</AU>
<TI>Treatment of endometriosis with a long acting gonadotropin-releasing hormone agonist plus medroxy-progesterone acetate</TI>
<SO>Obstetrics and Gynaecology</SO>
<YR>1990</YR>
<VL>75</VL>
<PG>641-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chatman-1982" MODIFIED="2008-08-20 16:16:40 +1200" MODIFIED_BY="[Empty name]" NAME="Chatman 1982" TYPE="JOURNAL_ARTICLE">
<AU>Chatman DL, Ward AB</AU>
<TI>Endometriosis in adolescents</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1982</YR>
<VL>27</VL>
<PG>156</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donnez-1997" MODIFIED="2008-08-20 16:17:20 +1200" MODIFIED_BY="[Empty name]" NAME="Donnez 1997" TYPE="JOURNAL_ARTICLE">
<AU>Donnez J, Nisolle M, Gillerot S, et al</AU>
<TI>Rectovaginal septum adenomyotic nodules: a series of 500 cases</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1997</YR>
<VL>104(9)</VL>
<PG>1014-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fedele-2004" MODIFIED="2008-08-20 16:17:50 +1200" MODIFIED_BY="[Empty name]" NAME="Fedele 2004" TYPE="JOURNAL_ARTICLE">
<AU>Fedele L, Bianchi S, Zanconato G, et al</AU>
<TI>Is rectovaginal endometriosis a progressive disease?</TI>
<SO>American Journel of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>191(5)</VL>
<PG>1539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haney-1991" MODIFIED="2008-08-20 16:25:14 +1200" MODIFIED_BY="[Empty name]" NAME="Haney 1991" TYPE="BOOK_SECTION">
<AU>Haney AF</AU>
<TI>The pathogenesis and etiology of endometriosis</TI>
<SO>Modern Approaches to Endometriosis</SO>
<YR>1991</YR>
<PG>3-19</PG>
<ED>Thomas E, Rock J</ED>
<PB>Kluver Academic Publishers</PB>
<CY>Dordrecht, The Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kitawaki-2002" MODIFIED="2008-08-20 16:25:59 +1200" MODIFIED_BY="[Empty name]" NAME="Kitawaki 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kitawaki J, Kado N, Koshiba H, Honjo H</AU>
<TI>Endometriosis: the pathophysiology as an estrogen-dependant disease</TI>
<SO>Journal of Steroid Biochemistry and Molecular Biology</SO>
<YR>2002</YR>
<VL>83</VL>
<NO>1-5</NO>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lindsay-1996" MODIFIED="2008-08-20 16:26:49 +1200" MODIFIED_BY="[Empty name]" NAME="Lindsay 1996" TYPE="JOURNAL_ARTICLE">
<AU>Lindsay PC, Show RW, Bennink HJ, Kicovic P</AU>
<TI>The effect of add-back treatment with tibolone (Livial) on patient treated with gonadotropin-releasing hormone against triptorelin (Decapeptyle)</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<PG>342-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Makarainen-1996" NAME="Makarainen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Makarainen L, Ronneberg L, Kauppila A</AU>
<TI>Medroxyprogesterone acetate supplementation diminishes the hypo-estrogenic side effects of gonadotropin-releasing hormone agonists without changing its efficacy in endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<PG>29-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Matorras-2002" MODIFIED="2008-08-20 16:27:22 +1200" MODIFIED_BY="[Empty name]" NAME="Matorras 2002" TYPE="JOURNAL_ARTICLE">
<AU>Matorras R, Elorriaga MA, Pijoan JI, Ramon O</AU>
<TI>Recurrence of endometriosis in women with bilateral adnexectomy (with or without total hysterectomy) who received hormone replacement therapy</TI>
<SO>Fertility and Sterility</SO>
<YR>2002</YR>
<VL>77</VL>
<NO>2</NO>
<PG>303-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riis-1990" NAME="Riis 1990" TYPE="JOURNAL_ARTICLE">
<AU>Riis B, Christiansen C, Johansen J, Jacobson J</AU>
<TI>Is it possible to prevent one loss in young women treated with luteinizing hormone-releasing hormone agonist?</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1990</YR>
<VL>70</VL>
<PG>920-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rock-1992" MODIFIED="2008-08-20 16:28:12 +1200" MODIFIED_BY="[Empty name]" NAME="Rock 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rock JA, Moutos DM</AU>
<TI>Endometriosis: the present and the future - an overview of treatment options</TI>
<SO>British Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>99 Suppl 7</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sagsaveen-2003" MODIFIED="2008-07-10 16:57:18 +1200" MODIFIED_BY="jane clarke" NAME="Sagsaveen 2003" TYPE="COCHRANE_REVIEW">
<AU>Sagsveen M, Farmer JE, Prentice A, Breeze A</AU>
<TI>Gonadotrophin-releasing hormone analogues for endometriosis: bone mineral density</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<PB>Chichester: Wiley</PB>
<IDENTIFIERS MODIFIED="2008-07-10 15:58:08 +1200" MODIFIED_BY="jane clarke">
<IDENTIFIER MODIFIED="2008-07-10 15:58:08 +1200" MODIFIED_BY="jane clarke" TYPE="DOI" VALUE="10.1002/14651858.CD001297"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sangi_x002d_Haghpeykar1995" NAME="Sangi-Haghpeykar1995" TYPE="JOURNAL_ARTICLE">
<AU>Sangi-Haghpeykar H, Poindexter AN</AU>
<TI>Epidemiology of endometriosis among parous women</TI>
<SO>Obstetrics and Gynaecology</SO>
<YR>1995</YR>
<VL>85</VL>
<PG>983</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shaw-1992" MODIFIED="2008-08-20 16:28:51 +1200" MODIFIED_BY="[Empty name]" NAME="Shaw 1992" TYPE="JOURNAL_ARTICLE">
<AU>Shaw RW</AU>
<TI>Treatment of endometriosis</TI>
<SO>Lancet</SO>
<YR>1992</YR>
<VL>340</VL>
<PG>1267-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slenvenson-1989" NAME="Slenvenson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Slenvenson JC, Lee B, Gardner R, Shaw RW</AU>
<TI>A comparison of the skeletal effects of goserlin and danazol in premenopausal women with endometriosis</TI>
<SO>Hormone Research</SO>
<YR>1989</YR>
<VL>32</VL>
<PG>161-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Surrey-1990" NAME="Surrey 1990" TYPE="JOURNAL_ARTICLE">
<AU>Surrey ES, Gambone JC, Lu JKH, Judd HL</AU>
<TI>The effects of combining norethindrone with a gonadotropin-releasing hormone agonist in the treatment of symptomatic endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1990</YR>
<VL>53</VL>
<PG>620-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Surrey-1992" NAME="Surrey 1992" TYPE="JOURNAL_ARTICLE">
<AU>Surrey E, Judd H</AU>
<TI>Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial</TI>
<SO>Journal of Clinical Endocrinology and Metabolism</SO>
<YR>1992</YR>
<VL>75</VL>
<PG>558-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tabkin-1997" NAME="Tabkin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Tabkin O, Yakinoghe AH, Kucuk S, Uryan I, Buhur A, Burak F</AU>
<TI>Effectiveness of tibolone on hypo-estrogenic symptoms induced by goserelin treatment in patients with endometriosis</TI>
<SO>Fertility and Sterility</SO>
<YR>1997</YR>
<VL>67</VL>
<PG>40-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-08-20 14:25:38 +1200" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-08-20 14:22:36 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-08-20 14:20:02 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fedele1999">
<CHAR_METHODS MODIFIED="2008-08-20 14:17:50 +1200" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>Computer-generated randomization.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-20 14:18:04 +1200" MODIFIED_BY="[Empty name]">
<P>Symptomatic patients with deeply infiltrating endometriotic nodules that recurred after one or more previous operations. Patients had bilateral oophorectomy with or without hysterectomy. The disease was not completely eradicated after the surgery.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-20 14:18:55 +1200" MODIFIED_BY="[Empty name]">
<P>Nonstop transdermal 17&#946;-estradiol 0.05 mg/d combined with cyclic medroxy progesterone acetate 10 mg/d for12 days/month in women with conserved uterus</P>
<P>Control: nonstop tibolone 2.5 mg/d.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-20 14:19:05 +1200" MODIFIED_BY="[Empty name]">
<P>Pain as reported by the patients at 3, 6, and 12 months after the start of the treatment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-08-20 14:20:02 +1200" MODIFIED_BY="[Empty name]">
<P>The duration of the treatment was at least 12 months.</P>
<P>All women were followed for 12 months and no participant suspended the therapy which indicates that intention to treat analysis was applied.</P>
<P>There was no blinding as the method of intervention and the control were different.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-08-20 14:22:36 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Matorras2002">
<CHAR_METHODS MODIFIED="2008-08-20 14:20:59 +1200" MODIFIED_BY="[Empty name]">
<P>RCT<BR/>The randomization was done using sealed envelopes. The randomization was done by a person not connected to the study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-20 14:22:24 +1200" MODIFIED_BY="[Empty name]">
<P>Women with histological diagnosis of endometriosis in whom BSO was done irrespective of associated surgical procedures.<BR/>No hormonal treatment during 6-month period before surgery.<BR/>No medical treatment of endometriosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-20 14:22:13 +1200" MODIFIED_BY="[Empty name]">
<P>Sequential administration of estrogen and progesterone following Belchetz's criteria<BR/>Two 22 cm<SUP>2</SUP> patches were applied per week which produced a controlled release of 50 microgram/day. Micronized progesterone was administered orally during 14 days, 200 mg/24 hours, with a 16-day interval free of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-08-20 14:22:36 +1200" MODIFIED_BY="[Empty name]">
<P>Recurrence of endometriosis that was diagnosed based on histological study, clinical findings, and ultrasound findings suggestive of endometriosis.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-07-10 16:20:53 +1200" MODIFIED_BY="jane clarke">
<P>There was no placebo but the women were all monitored by the same gynaecologist who was kept unaware of their treatment status.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-08-20 14:25:38 +1200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alexander-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-08-20 14:25:38 +1200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Arumugam-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-08-20 14:25:38 +1200" MODIFIED_BY="[Empty name]">
<P>No randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Attar-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bain-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Review and not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barrett_x002d_Connor-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Beard-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bianchi-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Part of Fedele 1999 study that was included</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bradshaw-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bulum-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chalas-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Colau-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Davis-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dennerstein-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dowsett-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Farquhar-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fedele-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Frackiewicz-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Friedlander-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ghezzi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goulding-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Graziottin-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hackman-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hansen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holub-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>No appropriate randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Holub-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>No appropriate randomization</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hu-W_x002d_P-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ivanov-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jelovsek-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Johnson-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jones-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jordan-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kenemans-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Khastgir-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kiesel-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kitawaki-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kouides-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kroon-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuenzel-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Editors' highlight</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuohung-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kuzel-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lalchandani-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leyendecker-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobo-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loizzi-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>UNrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Long-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lopez_x002d_Olmos-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lu-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Luciano-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mannix-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mendoza-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mizutani-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Modugno-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Moen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Morini-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mousa-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murphy-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagao-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nagata-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Namnoum-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nappi-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nasir-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Noble-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozawa-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ozols-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perry-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piltonen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pruthi-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Purdie-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rattanachaiyanont-03">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rees-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Reid-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robson-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Roman-2007">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rotella-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Santos-Gonzalez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schor-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Schwenkhagen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Setnikar-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tan-2008">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tietjen-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tok-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Uemura-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Usman-2008">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Varma-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Velasco-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vercellini-2008">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Weiss-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Winkel-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic<BR/>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolff-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wolff-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wylie-2006">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yohannes-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unrelated topic</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-21 09:47:22 +1200" MODIFIED_BY="jane clarke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2008-07-15 17:41:21 +1200" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-15 09:02:47 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>Randomization was computer generated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-15 17:41:21 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>The randomization was done using sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-08-20 14:25:26 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-15 09:03:12 +1200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>Unclear, the method was not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-20 14:25:26 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>Adequate, randomization was done by a person not related to the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-08-21 09:47:22 +1200" MODIFIED_BY="jane clarke" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-07-15 09:04:05 +1200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>The intervention and control were different</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-21 09:47:22 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>There was no blinding except for the assessing gynaecologist who was kept unaware of treatment status</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2008-08-20 14:23:54 +1200" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-20 14:20:30 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>The reported outcome was clear: pain as reported by the patient at 3, 6, and 12 months after the start of the treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2008-08-20 14:23:54 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>There was a clearly adressed outcome: recurrence of endometriosis that was diagnosed based on histological study, clinical findings, and ultrasound findings suggestive of endometriosis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2008-08-20 14:23:58 +1200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-16 01:28:05 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>The reported outcome was clear and as planned in the methodology</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-20 14:23:58 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>The report included the selected outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2008-08-21 09:47:18 +1200" MODIFIED_BY="jane clarke" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-21 09:47:18 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Fedele1999">
<DESCRIPTION>
<P>Apart from blinding's and allocation concealment, there was no other bias</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-08-20 14:24:10 +1200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Matorras2002">
<DESCRIPTION>
<P>Apart from blinding, no other bias identified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-07-14 15:59:19 +1200" MODIFIED_BY="jane clarke"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-07-29 18:10:29 +1200" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Estrogen with or without progesterone versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="87.70723951153764" CI_START="0.2456040540604222" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="4.641255605381166" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="1.9430354422845117" LOG_CI_START="-0.60976446879496" LOG_EFFECT_SIZE="0.6666354867447759" METHOD="MH" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.30600258471123043" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="57" WEIGHT="100.0" Z="1.0236458714726224">
<NAME>Number of patients reporting pain</NAME>
<GROUP_LABEL_1>Estrogen +/- prog</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no treat</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="87.70723951153764" CI_START="0.2456040540604222" EFFECT_SIZE="4.641255605381166" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.9430354422845117" LOG_CI_START="-0.60976446879496" LOG_EFFECT_SIZE="0.6666354867447759" ORDER="1" O_E="0.0" SE="1.4995273043314414" STUDY_ID="STD-Matorras2002" TOTAL_1="115" TOTAL_2="57" VAR="2.248582136435519" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="53.640954262234146" CI_START="0.11961550543695049" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5330396475770924" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.7294964952633838" LOG_CI_START="-0.9222125202703682" LOG_EFFECT_SIZE="0.40364198749650776" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.5507145588007505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="57" WEIGHT="100.0" Z="0.5966897223691643">
<NAME>Recurrence confirmed by histopathology</NAME>
<GROUP_LABEL_1>Estrogen +/- prog</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="53.640954262234146" CI_START="0.11961550543695049" EFFECT_SIZE="2.5330396475770924" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7294964952633838" LOG_CI_START="-0.9222125202703682" LOG_EFFECT_SIZE="0.40364198749650776" ORDER="2" O_E="0.0" SE="1.557627001895849" STUDY_ID="STD-Matorras2002" TOTAL_1="115" TOTAL_2="57" VAR="2.4262018770350506" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="53.640954262234146" CI_START="0.11961550543695049" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5330396475770924" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.7294964952633838" LOG_CI_START="-0.9222125202703682" LOG_EFFECT_SIZE="0.40364198749650776" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5507145588007505" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="57" WEIGHT="100.0" Z="0.5966897223691643">
<NAME>Re-operation</NAME>
<GROUP_LABEL_1>Estrogen+/- prog</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo/no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="53.640954262234146" CI_START="0.11961550543695049" EFFECT_SIZE="2.5330396475770924" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7294964952633838" LOG_CI_START="-0.9222125202703682" LOG_EFFECT_SIZE="0.40364198749650776" ORDER="3" O_E="0.0" SE="1.557627001895849" STUDY_ID="STD-Matorras2002" TOTAL_1="115" TOTAL_2="57" VAR="2.4262018770350506" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-07-29 18:10:29 +1200" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Estrogen with or without progesterone versus tibolone</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.50564163344833" CI_START="0.5965245512964175" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="6.666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.8721891591578252" LOG_CI_START="-0.22437167726918777" LOG_EFFECT_SIZE="0.8239087409443188" METHOD="MH" MODIFIED="2008-07-29 18:10:29 +1200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="0.0" P_Z="0.12344886860421868" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10" TOTAL_2="11" WEIGHT="100.0" Z="1.5404575252398816">
<NAME>Number of patients reporting pain</NAME>
<GROUP_LABEL_1>Estrogen +/- prog</GROUP_LABEL_1>
<GROUP_LABEL_2>Tibolone</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.50564163344833" CI_START="0.5965245512964175" EFFECT_SIZE="6.666666666666667" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.8721891591578252" LOG_CI_START="-0.22437167726918777" LOG_EFFECT_SIZE="0.8239087409443188" ORDER="4" O_E="0.0" SE="1.2315302134607444" STUDY_ID="STD-Fedele1999" TOTAL_1="10" TOTAL_2="11" VAR="1.5166666666666666" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-10-22 17:11:22 +1300" MODIFIED_BY="jane clarke">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-10-22 17:11:15 +1300" MODIFIED_BY="jane clarke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2008-10-22 17:11:22 +1300" MODIFIED_BY="jane clarke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARkAAAEmCAIAAADZXnM4AAAMRUlEQVR42u3dvW4kRReH8ZFICBw4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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-07-10 15:51:24 +1200" MODIFIED_BY="jane clarke">
<APPENDIX ID="APP-01" MODIFIED="2008-07-10 15:51:24 +1200" MODIFIED_BY="jane clarke" NO="1">
<TITLE MODIFIED="2008-07-10 15:43:07 +1200" MODIFIED_BY="jane clarke">MEDLINE</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-10 15:51:24 +1200" MODIFIED_BY="jane clarke">
<P>
<B>MEDLINE search strategy (1950 to 18 March 2008)<BR/>
</B>1 exp Endometriosis/ (12393)<BR/>2 Endometriosis.tw. (10555)<BR/>3 exp Pelvic Pain/ (4372)<BR/>4 (Pelvic adj2 Pain).tw. (3537)<BR/>5 Dyspareunia/ (938)<BR/>6 Dyschezia$.tw. (98)<BR/>7 Dyspareunia$.tw. (1433)<BR/>8 (pain$ adj2 bowel movement$).tw. (40)<BR/>9 exp Ovariectomy/ (15381)<BR/>10 Ovariectom$.tw. (17565)<BR/>11 oophorect$.tw. (4897)<BR/>12 (remov$ adj2 ovar$).tw. (772)<BR/>13 (salpingo adj ovariectomy).tw. (7)<BR/>14 (surgic$ adj3 menopause).tw. (504)<BR/>15 or/1-8 (20739)<BR/>16 or/9-14 (27561)<BR/>17 15 and 16 (626)<BR/>18 exp hormone replacement therapy/ or exp estrogen replacement therapy/ (16022)<BR/>19 (Hormone adj2 therap$).tw. (15598)<BR/>20 HRT.tw. (5476)<BR/>21 Tibolone.tw. (640)<BR/>22 exp Estrogens/ (120957)<BR/>23 exp Progesterone/ (56827)<BR/>24 (Estrogen$ or Progest$).tw. (120763)<BR/>25 or/18-24 (210538)<BR/>26 17 and 25 (173)<BR/>27 randomised controlled trial.pt. (251334)<BR/>28 controlled clinical trial.pt. (77422)<BR/>29 randomised controlled trials as topic/ (53023)<BR/>30 random allocation/ (60395)<BR/>31 double blind method/ (96065)<BR/>32 single blind method/ (11789)<BR/>33 or/27-32 (424467)<BR/>34 animals/ not (animals/ and humans/) (3189559)<BR/>35 33 not 34 (397756)<BR/>36 clinical trial.pt. (446433)<BR/>37 exp clinical trials as topic/ (201557)<BR/>38 (clinic$ adj25 trial$).ti,ab. (142061)<BR/>39 cross-over studies/ (21493)<BR/>40 (crossover or cross-over or cross over).tw. (40169)<BR/>41 ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab. (95360)<BR/>42 placebos/ (26962)<BR/>43 placebo$.ti,ab. (108242)<BR/>44 random$.ti,ab. (401463)<BR/>45 research design/ (51618)<BR/>46 or/36-45 (910204)<BR/>47 46 not 34 (843399)<BR/>48 35 or 47 (865071)<BR/>49 26 and 48 (14)<BR/>50 from 49 keep 1-14 (14)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-07-10 15:43:58 +1200" MODIFIED_BY="jane clarke" NO="2">
<TITLE MODIFIED="2008-07-10 15:43:55 +1200" MODIFIED_BY="jane clarke">Psych INFO</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-10 15:43:58 +1200" MODIFIED_BY="jane clarke">
<P>1 exp Endometriosis/ (0)<BR/>2 Endometriosis.tw. (91)<BR/>3 exp Pelvic Pain/ (0)<BR/>4 (Pelvic adj2 Pain).tw. (248)<BR/>5 Dyspareunia/ (134)<BR/>6 Dyschezia$.tw. (3)<BR/>7 Dyspareunia$.tw. (267)<BR/>8 (pain$ adj2 bowel movement$).tw. (6)<BR/>9 exp Ovariectomy/ (1115)<BR/>10 Ovariectom$.tw. (2403)<BR/>11 oophorect$.tw. (108)<BR/>12 (remov$ adj2 ovar$).tw. (40)<BR/>13 (salpingo adj ovariectomy).tw. (0)<BR/>14 (surgic$ adj3 menopause).tw. (64)<BR/>15 or/1-8 (589)<BR/>16 or/9-14 (2634)<BR/>17 15 and 16 (3)<BR/>18 exp hormone replacement therapy/ or exp estrogen replacement therapy/ (1056)<BR/>19 (Hormone adj2 therap$).tw. (971)<BR/>20 HRT.tw. (361)<BR/>21 Tibolone.tw. (18)<BR/>22 exp Estrogens/ (3495)<BR/>23 exp Progesterone/ (1390)<BR/>24 (Estrogen$ or Progest$).tw. (5595)<BR/>25 or/18-24 (7349)<BR/>26 17 and 25 (1)<BR/>27 from 26 keep 1 (1)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-07-10 15:44:22 +1200" MODIFIED_BY="jane clarke" NO="3">
<TITLE MODIFIED="2008-07-10 15:44:19 +1200" MODIFIED_BY="jane clarke">CINAHL</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-10 15:44:22 +1200" MODIFIED_BY="jane clarke">
<P>1 exp Endometriosis/ (566)<BR/>2 Endometriosis.tw. (463)<BR/>3 exp Pelvic Pain/ (775)<BR/>4 (Pelvic adj2 Pain).tw. (517)<BR/>5 Dyspareunia/ (150)<BR/>6 Dyschezia$.tw. (1)<BR/>7 Dyspareunia$.tw. (143)<BR/>8 (pain$ adj2 bowel movement$).tw. (5)<BR/>9 exp Ovariectomy/ (448)<BR/>10 Ovariectom$.tw. (145)<BR/>11 oophorect$.tw. (276)<BR/>12 (remov$ adj2 ovar$).tw. (20)<BR/>13 (salpingo adj ovariectomy).tw. (0)<BR/>14 (surgic$ adj3 menopause).tw. (76)<BR/>15 or/1-8 (1672)<BR/>16 or/9-14 (674)<BR/>17 15 and 16 (35)<BR/>18 exp hormone replacement therapy/ or exp estrogen replacement therapy/ (4517)<BR/>19 (Hormone adj2 therap$).tw. (2363)<BR/>20 HRT.tw. (1006)<BR/>21 Tibolone.tw. (57)<BR/>22 exp Estrogens/ (4247)<BR/>23 exp Progesterone/ (788)<BR/>24 (Estrogen$ or Progest$).tw. (3460)<BR/>25 estra$.tw. (790)<BR/>26 or/18-25 (9451)<BR/>27 17 and 26 (10)<BR/>28 exp clinical trials/ (57427)<BR/>29 Clinical trial.pt. (29998)<BR/>30 (clinic$ adj trial$1).tw. (13150)<BR/>31 ((singl$ or doubl$ or trebl$ or tripl$) adj (blind$3 or mask$3)).tw. (7801)<BR/>32 Randomi?ed control$ trial$.tw. (11197)<BR/>33 Random assignment/ (17445)<BR/>34 Random$ allocat$.tw. (1211)<BR/>35 Placebo$.tw. (10846)<BR/>36 Placebos/ (4145)<BR/>37 Quantitative studies/ (3735)<BR/>38 Allocat$ random$.tw. (73)<BR/>39 or/28-38 (79254)<BR/>40 27 and 39 (2)<BR/>41 from 40 keep 1-2 (2)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-07-10 15:44:48 +1200" MODIFIED_BY="jane clarke" NO="4">
<TITLE MODIFIED="2008-07-10 15:44:46 +1200" MODIFIED_BY="jane clarke">CENTRAL</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-10 15:44:48 +1200" MODIFIED_BY="jane clarke">
<P>1 exp Endometriosis/ (347)<BR/>2 Endometriosis.tw. (581)<BR/>3 Pelvis Pain Syndrome/ (0)<BR/>4 (Pelvic adj2 Pain).tw. (309)<BR/>5 Dyspareunia/ (43)<BR/>6 Dyspareunia$.tw. (133)<BR/>7 Dyschezia$.tw. (4)<BR/>8 (pain$ adj2 bowel movement$).tw. (13)<BR/>9 exp ovariectomy/ or exp salpingooophorectomy/ (190)<BR/>10 Ovariectom$.tw. (65)<BR/>11 salpingooophorectom$.tw. (1)<BR/>12 oophorect$.tw. (293)<BR/>13 (remov$ adj2 ovar$).tw. (11)<BR/>14 (salpingo adj ovariectomy).tw. (0)<BR/>15 (surgic$ adj3 menopause).tw. (76)<BR/>16 or/1-8 (954)<BR/>17 or/9-15 (472)<BR/>18 16 and 17 (20)<BR/>19 exp Hormone Substitution/ (0)<BR/>20 (Hormone adj2 therap$).tw. (2360)<BR/>21 (hormone adj3 substitut$).tw. (53)<BR/>22 HRT.tw. (1012)<BR/>23 exp Tibolone/ (0)<BR/>24 Tibolone.tw. (309)<BR/>25 exp Estrogen/ (3675)<BR/>26 exp Progesterone/ (1787)<BR/>27 tibolone.tw. (309)<BR/>28 (Estrogen$ or Progest$).tw. (5916)<BR/>29 estra$.tw. (3383)<BR/>30 or/19-29 (10176)<BR/>31 18 and 30 (8)<BR/>32 from 31 keep 1-8 (8)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-07-10 15:45:12 +1200" MODIFIED_BY="jane clarke" NO="5">
<TITLE MODIFIED="2008-07-10 15:45:09 +1200" MODIFIED_BY="jane clarke">EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-10 15:45:12 +1200" MODIFIED_BY="jane clarke">
<P>1 exp Endometriosis/ (10166)<BR/>2 Endometriosis.tw. (8803)<BR/>3 Pelvis Pain Syndrome/ (4221)<BR/>4 (Pelvic adj2 Pain).tw. (3474)<BR/>5 Dyspareunia/ (2069)<BR/>6 Dyspareunia$.tw. (1403)<BR/>7 Dyschezia$.tw. (79)<BR/>8 (pain$ adj2 bowel movement$).tw. (36)<BR/>9 exp ovariectomy/ or exp salpingooophorectomy/ (18093)<BR/>10 Ovariectom$.tw. (14109)<BR/>11 salpingooophorectom$.tw. (107)<BR/>12 oophorect$.tw. (4363)<BR/>13 (remov$ adj2 ovar$).tw. (576)<BR/>14 (salpingo adj ovariectomy).tw. (7)<BR/>15 (surgic$ adj3 menopause).tw. (481)<BR/>16 or/1-8 (16927)<BR/>17 or/9-15 (24421)<BR/>18 16 and 17 (830)<BR/>19 exp Hormone Substitution/ (25640)<BR/>20 (Hormone adj2 therap$).tw. (14911)<BR/>21 (hormone adj3 substitut$).tw. (640)<BR/>22 HRT.tw. (6186)<BR/>23 exp Tibolone/ (1638)<BR/>24 Tibolone.tw. (754)<BR/>25 exp Estrogen/ (117030)<BR/>26 exp Progesterone/ (37148)<BR/>27 tibolone.tw. (754)<BR/>28 (Estrogen$ or Progest$).tw. (95948)<BR/>29 estra$.tw. (44850)<BR/>30 or/19-29 (183085)<BR/>31 18 and 30 (280)<BR/>32 Clinical trial/ (495185)<BR/>33 Randomized controlled trials/ (155511)<BR/>34 Random Allocation/ (25203)<BR/>35 Single-Blind Method/ (7410)<BR/>36 Double-Blind Method/ (68576)<BR/>37 Cross-Over Studies/ (20046)<BR/>38 Placebos/ (111054)<BR/>39 Randomi?ed controlled trial$.tw. (28060)<BR/>40 RCT.tw. (2194)<BR/>41 Random allocation.tw. (605)<BR/>42 Randomly allocated.tw. (9592)<BR/>43 Allocated randomly.tw. (1314)<BR/>44 (allocated adj2 random).tw. (552)<BR/>45 Single blind$.tw. (7066)<BR/>46 Double blind$.tw. (81296)<BR/>47 ((treble or triple) adj blind$).tw. (127)<BR/>48 Placebo$.tw. (104327)<BR/>49 Prospective Studies/ (73142)<BR/>50 or/32-49 (651841)<BR/>51 Case study/ (5369)<BR/>52 Case report.tw. (110903)<BR/>53 Abstract report/ or letter/ (461484)<BR/>54 or/51-53 (575754)<BR/>55 50 not 54 (629234)<BR/>56 animal/ (18235)<BR/>57 human/ (6058876)<BR/>58 56 not 57 (14465)<BR/>59 55 not 58 (629138)<BR/>60 31 and 59 (49)<BR/>61 from 60 keep 1-49 (49)</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>